Genetic background regulates β-amyloid precursor protein processing and β-amyloid deposition in the mouse

被引:75
作者
Lehman, EJH
Kulnane, LS
Gao, Y
Petriello, MC
Pimpis, KM
Younkin, L
Dolios, G
Wang, R
Younkin, SG
Lamb, BT
机构
[1] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA
[4] Univ Hosp Cleveland, Univ Memory & Aging Ctr, Ctr Human Genet, Cleveland, OH 44106 USA
[5] Mayo Fdn Med Educ & Res, Ctr Neurosci, Jacksonville, FL 32224 USA
[6] Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA
关键词
D O I
10.1093/hmg/ddg322
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a multigenic neurodegenerative disorder characterized by distinct neuropathological hallmarks including deposits of the beta-amyloid (Abeta) peptide. Abeta is a 39- to 43-amino acid peptide derived from the proteolytic processing of the amyloid precursor protein (APP). While increasing evidence suggests that altered APP processing and Abeta metabolism is a common feature of AD, the relationship between the levels of Abeta and various APP products and the onset of AD remains unclear. We have undertaken a screen to characterize genetic factors that modify APP processing, Abeta metabolism and Abeta deposition in a genomic-based yeast artificial chromosome (YAC) transgenic mouse model of AD. A mutant human APP YAC transgene was transferred to three inbred mouse strains. Despite similar levels of holo-APP expression in the congenic strains, the levels of APP C-terminal fragments as well as brain and plasma Abeta in young animals varied by genetic background. Furthermore, we demonstrate that age-dependent Abeta deposition in the APP YAC transgenic model is dramatically altered depending on the congenic strain examined. These studies demonstrate that APP processing, Abeta metabolism and Abeta deposition are regulated by genetic background and that analysis of these phenotypes in mice should provide new insights into the factors that regulate AD pathogenesis.
引用
收藏
页码:2949 / 2956
页数:8
相关论文
共 40 条
[1]   Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene [J].
Axelman, K ;
Basun, H ;
Lannfelt, L .
ARCHIVES OF NEUROLOGY, 1998, 55 (05) :698-702
[2]   Consensus recommendations for the postmortem diagnosis of Alzheimer's disease [J].
Ball, M ;
Braak, H ;
Coleman, P ;
Dickson, D ;
Duyckaerts, C ;
Gambetti, P ;
Hansen, L ;
Hyman, B ;
Jellinger, K ;
Markesbery, W ;
Perl, D ;
Powers, J ;
Price, J ;
Trojanowski, JQ ;
Wisniewski, H ;
Phelps, C ;
Khachaturian, Z .
NEUROBIOLOGY OF AGING, 1997, 18 (04) :S1-S2
[3]   Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins [J].
Borchelt, DR ;
Ratovitski, T ;
vanLare, J ;
Lee, MK ;
Gonzales, V ;
Jenkins, NA ;
Copeland, NG ;
Price, DL ;
Sisodia, SS .
NEURON, 1997, 19 (04) :939-945
[4]   Diagnostic approaches to Alzheimer's disease [J].
Boss, MA .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2000, 1502 (01) :188-200
[5]   Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset [J].
Brookmeyer, R ;
Gray, S ;
Kawas, C .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (09) :1337-1342
[6]   Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice [J].
Carlson, GA ;
Borchelt, DR ;
Dake, A ;
Turner, S ;
Danielson, V ;
Coffin, JD ;
Eckman, C ;
Meiners, J ;
Nilsen, SP ;
Younkin, SG ;
Hsiao, KK .
HUMAN MOLECULAR GENETICS, 1997, 6 (11) :1951-1959
[7]   Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695 [J].
Chishti, MA ;
Yang, DS ;
Janus, C ;
Phinney, AL ;
Horne, P ;
Pearson, J ;
Strome, R ;
Zuker, N ;
Loukides, J ;
French, J ;
Turner, S ;
Lozza, G ;
Grilli, M ;
Kunicki, S ;
Morissette, C ;
Paquette, J ;
Gervais, F ;
Bergeron, C ;
Fraser, PE ;
Carlson, GA ;
St George-Hyslop, P ;
Westaway, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (24) :21562-21570
[8]   Alzheimer disease [J].
Cummings, JL ;
Cole, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (18) :2335-2338
[9]   Evidence that Aβ42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype [J].
De Jonghe, C ;
Cras, P ;
Vanderstichele, H ;
Cruts, M ;
Vanderhoeven, I ;
Smouts, I ;
Vanmechelen, E ;
Martin, JJ ;
Hendriks, L ;
Van Broeckhoven, C .
NEUROBIOLOGY OF DISEASE, 1999, 6 (04) :280-287
[10]   Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].
DeMattos, RB ;
Bales, KR ;
Cummins, DJ ;
Dodart, JC ;
Paul, SM ;
Holtzman, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855